Hunniwell's Series B Investment CoapTech was recently awarded $1.6 Million from NIH to finalize the development and trial of its Pediatric PUMA-G System.
HLV Founding Managing Partner Richard Fang shares his personal entrepreneurial experience, as well as the motivation and the differentiating strategies behind the Hunniwell Medical Device Fund.
WaveClear, Inc. announces the closing of a $1,125,000 Series-A round of investment led by Hunniwell Lake Ventures. They will use their funds to further develop the CaviClearTM Endovascular System, a minimally invasive and cost-effective ultrasound generated cavitation device for a broad range of endovascular applications.
CoapTech has closed a Series B investment of $7 million led by Hunniwell. The funds will be used to commercialize the First FDA-cleared, Ultrasound-based system for Feeding Tube Placement.
Hunniwell Lake Ventures (HLV) is pleased to sponsor this year’s Spring F50 Global Capital Summit, June 16-17, 2020. Watch HLV partners give talks, host live roundtables, speak on panels and judge startups.
Hunniwell Lake Ventures is pleased to gain the strategic counsel of these talented, highly experienced and successful professionals - David Schechter, David Cao, John Ashley and Matt Otten - as they help us achieve our mission towards Intelligent Surgery.
Hunniwell Lake Ventures Managing Partner Daniel Teo shares keen advice with the inaugural class of 2020 Fellows in the UCLA BioDesign Program in his presentation titled "Tales from the Other Side."
Hunniwell Lake Ventures joined 60 other experts in the medical device industry to help 15 selected startups accelerate the development and commercialization of their COVID-19 related solution.